

# Ichiro Ieiri

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4092078/ichiro-ieiri-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97  
papers

4,892  
citations

35  
h-index

69  
g-index

106  
ext. papers

5,265  
ext. citations

3.7  
avg. IF

5.14  
L-index

#	Paper	IF	Citations
97	Simplified daptomycin dosing regimen for adult patients with methicillin-resistant <i>Staphylococcus aureus</i> infections based on population pharmacokinetic analysis.. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2022</b> , 44, 100444	2.2	
96	Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin's Lymphoma Receiving ESHAP Therapy.. <i>Anticancer Research</i> , <b>2022</b> , 42, 2053-2060	2.3	
95	Evaluation of Medication Instruction Sheets for Patients Undergoing R-CHOP Therapy in Non-Hodgkin's Lymphoma.. <i>In Vivo</i> , <b>2022</b> , 36, 1461-1467	2.3	
94	Hypoglycemia possibly caused by CYP2C9-mediated drug interaction in combination with bucolome: a case report. <i>Journal of Pharmaceutical Health Care and Sciences</i> , <b>2021</b> , 7, 39	1.8	1
93	The mTOR inhibitor everolimus attenuates tacrolimus-induced renal interstitial fibrosis in rats. <i>Life Sciences</i> , <b>2021</b> , 288, 120150	6.8	2
92	Detection of overdose and underdose prescriptions-An unsupervised machine learning approach. <i>PLoS ONE</i> , <b>2021</b> , 16, e0260315	3.7	1
91	Effects of Letemovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study. <i>Drugs in R and D</i> , <b>2021</b> , 21, 419-429	3.4	1
90	Establishment of an experimental rat model of tacrolimus-induced kidney injury accompanied by interstitial fibrosis. <i>Toxicology Letters</i> , <b>2021</b> , 341, 43-50	4.4	1
89	Reduced theophylline clearance due to hepatic congestion secondary to right heart failure - A population pharmacokinetic study. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2021</b> , 41, 100403	2.2	0
88	Risk Factors for Gemcitabine-Induced Vascular Pain in Patients With Pancreatic Cancer. <i>Annals of Pharmacotherapy</i> , <b>2021</b> , 55, 738-744	2.9	0
87	Effect of Genetic Polymorphisms of Human SLC22A3 in the 5'Flanking Region on OCT3 Expression and Sebum Levels in Human Skin. <i>Journal of Dermatological Science</i> , <b>2021</b> , 101, 4-13	4.3	0
86	Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy. <i>Scientific Reports</i> , <b>2021</b> , 11, 15057	4.9	2
85	Development and Full Validation of a Bioanalytical Method for Quantifying Letemovir in Human Plasma Using Ultra-Performance Liquid Chromatography Coupled with Mass Spectrometry. <i>Chemical and Pharmaceutical Bulletin</i> , <b>2021</b> , 69, 646-651	1.9	
84	Experimental Survey of Anticancer Drug Contamination from Disposal Containers to Prevent Occupational Exposure. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2021</b> , 47, 200-207	0.1	
83	Regulation of Organic Anion Transporting Polypeptide 2B1 Expression by MicroRNA in the Human Liver. <i>Molecular Pharmaceutics</i> , <b>2020</b> , 17, 2821-2830	5.6	3
82	Differences in Theophylline Clearance Between Patients With Chronic Hepatitis and Those With Liver Cirrhosis. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 829-834	3.2	2
81	An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2020</b> , 16, 809-822	5.5	21

80	Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 86, 803-813	3.5	8
79	Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer. <i>Clinical Pharmacokinetics</i> , <b>2019</b> , 58, 403-420	6.2	18
78	Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 393-402	3.8	10
77	Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation. <i>European Journal of Clinical Pharmacology</i> , <b>2019</b> , 75, 351-361	2.8	2
76	Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2019</b> , 34, 78-86	2.2	35
75	Identification of drug transporters contributing to oxaliplatin-induced peripheral neuropathy. <i>Journal of Neurochemistry</i> , <b>2019</b> , 148, 373-385	6	31
74	Interindividual Differences in the Expression of ATP-Binding Cassette and Solute Carrier Family Transporters in Human Skin: DNA Methylation Regulates Transcriptional Activity of the Human ABCC3 Gene. <i>Drug Metabolism and Disposition</i> , <b>2018</b> , 46, 628-635	4	15
73	The relationship between fine particulate matter (PM) and schizophrenia severity. <i>International Archives of Occupational and Environmental Health</i> , <b>2018</b> , 91, 613-622	3.2	9
72	Population Pharmacodynamic Analysis of Uric Acid-Lowering Effects of Febuxostat Based on Electronic Medical Records in Two Hospitals. <i>Journal of Clinical Pharmacology</i> , <b>2018</b> , 58, 304-313	2.9	1
71	Relationship between DNA Methylation in the 5PCpG Island of the (Multidrug and Toxin Extrusion Protein MATE1) Gene and Interindividual Variability in MATE1 Expression in the Human Liver. <i>Molecular Pharmacology</i> , <b>2018</b> , 93, 1-7	4.3	5
70	Characterization of changes in HbA1c in patients with and without secondary failure after metformin treatments by a population pharmacodynamic analysis using mixture models. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2018</b> , 33, 264-269	2.2	1
69	Nucleosome Positioning and Gene Regulation of the Gene in the Renal Proximal Tubular Epithelial Cells. <i>Molecular Pharmacology</i> , <b>2018</b> , 94, 953-962	4.3	4
68	Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. <i>Journal of Pharmaceutical Sciences</i> , <b>2017</b> , 106, 2688-2694	3.9	34
67	Epigenetic regulation of drug transporter expression in human tissues. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2017</b> , 13, 19-30	5.5	14
66	Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records. <i>Journal of Diabetes and Its Complications</i> , <b>2016</b> , 30, 1282-6	3.2	1
65	Circulating intestine-derived exosomal miR-328 in plasma, a possible biomarker for estimating BCRP function in the human intestines. <i>Scientific Reports</i> , <b>2016</b> , 6, 32299	4.9	16
64	Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information. <i>Drug Metabolism and Disposition</i> , <b>2016</b> , 44, 1622-32	4	35
63	Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 78, 1013-1023	3.5	15

62	Drug-drug interactions that interfere with statin metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2015</b> , 11, 1435-47	5.5	48
61	The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2015</b> , 30, 352-7	2.2	22
60	Pharmacokinetics of levodopa/benserazide versus levodopa/carbidopa in healthy subjects and patients with Parkinson's disease. <i>Neurology and Clinical Neuroscience</i> , <b>2015</b> , 3, 68-73	0.3	18
59	Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 80, 1236-7	3.8	17
58	Population pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-medications based on electronic medical records. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 78, 824-35	3.8	11
57	Identification and functional characterization of novel nonsynonymous variants in the human multidrug and toxin extrusion 2-K. <i>Drug Metabolism and Disposition</i> , <b>2014</b> , 42, 1432-7	4	7
56	Apple juice greatly reduces systemic exposure to atenolol. <i>British Journal of Clinical Pharmacology</i> , <b>2013</b> , 75, 172-9	3.8	45
55	Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions. <i>Pharmacogenomics</i> , <b>2013</b> , 14, 1745-64	2.6	14
54	Association between DNA methylation in the miR-328 5Pflanking region and inter-individual differences in miR-328 and BCRP expression in human placenta. <i>PLoS ONE</i> , <b>2013</b> , 8, e72906	3.7	16
53	Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. <i>British Journal of Pharmacology</i> , <b>2012</b> , 166, 1793-803	8.6	104
52	Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). <i>Drug Metabolism and Pharmacokinetics</i> , <b>2012</b> , 27, 85-105	2.2	113
51	Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. <i>Journal of Clinical Pharmacology</i> , <b>2012</b> , 52, 1078-89	2.9	79
50	Association of multidrug resistance-associated protein 2 single nucleotide polymorphism rs12762549 with the basal plasma levels of phase II metabolites of isoflavonoids in healthy Japanese individuals. <i>Pharmacogenetics and Genomics</i> , <b>2012</b> , 22, 344-54	1.9	15
49	Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. <i>Pharmacogenetics and Genomics</i> , <b>2011</b> , 21, 495-505	1.9	41
48	Systematic screening of human ABCC3 polymorphisms and their effects on MRP3 expression and function. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2011</b> , 26, 374-86	2.2	15
47	Interindividual differences in placental expression of the SLC22A2 (OCT2) gene: relationship to epigenetic variations in the 5Pupstream regulatory region. <i>Journal of Pharmaceutical Sciences</i> , <b>2011</b> , 100, 3875-83	3.9	20
46	Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice. <i>Journal of Pharmacy and Pharmacology</i> , <b>2010</b> , 61, 615-621	4.8	3
45	Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2009</b> , 5, 703-20	5.5	167

44	Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 63, 1165-9	3.5	42
43	Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic Information on SLCO1B1 and ABCC2 polymorphisms. <i>Journal of Clinical Pharmacology</i> , <b>2009</b> , 49, 1309-17	2.9	18
42	Polymorphism in human organic cation transporters and metformin action. <i>Pharmacogenomics</i> , <b>2008</b> , 9, 415-22	2.6	104
41	Epigenetic regulation of genes encoding drug-metabolizing enzymes and transporters; DNA methylation and other mechanisms. <i>Current Drug Metabolism</i> , <b>2008</b> , 9, 34-8	3.5	27
40	Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism. <i>Journal of Human Genetics</i> , <b>2008</b> , 53, 899-904	4.3	32
39	1.?????PGx. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , <b>2008</b> , 39, 233-237	0	
38	Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. <i>Journal of Human Genetics</i> , <b>2007</b> , 52, 117-122	4.3	153
37	Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. <i>Therapeutic Drug Monitoring</i> , <b>2007</b> , 29, 666-8	3.2	32
36	Multiple gene polymorphisms and warfarin sensitivity. <i>European Journal of Clinical Pharmacology</i> , <b>2006</b> , 62, 881-3	2.8	4
35	Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2006</b> , 2, 651-74	5.5	42
34	Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. <i>Pharmacogenetics and Genomics</i> , <b>2006</b> , 16, 101-10	1.9	285
33	Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 79, 427-39	6.1	156
32	Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. <i>Journal of Human Genetics</i> , <b>2006</b> , 51, 822-826	4.3	57
31	Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using <sup>11</sup> C-verapamil. <i>Journal of Nuclear Medicine</i> , <b>2006</b> , 47, 1427-33	8.9	69
30	Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status. <i>Pharmacogenetics and Genomics</i> , <b>2005</b> , 15, 851-9	1.9	23
29	Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. <i>Drug Metabolism and Disposition</i> , <b>2005</b> , 33, 94-101	4	241
28	Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. <i>Human Molecular Genetics</i> , <b>2004</b> , 13, 2959-69	5.6	44
27	Functional analysis of SNPs variants of BCRP/ABCG2. <i>Pharmaceutical Research</i> , <b>2004</b> , 21, 1895-903	4.5	215

26	Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects. <i>Hepatology Research</i> , <b>2004</b> , 30, 91-95	5.1	41
25	The MDR1 (ABCB1) gene polymorphism and its clinical implications. <i>Clinical Pharmacokinetics</i> , <b>2004</b> , 43, 553-76	6.2	113
24	Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). <i>Pharmacogenetics and Genomics</i> , <b>2004</b> , 14, 749-57		130
23	5Pflanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. <i>Blood</i> , <b>2004</b> , 103, 3055-7	2.2	40
22	Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. <i>Blood</i> , <b>2004</b> , 103, 2630-5	2.2	137
21	Simultaneous determination of carbamate pesticides in human serum and urine by automatic reversed-phase HPLC combined with on-line column enrichment. <i>Bunseki Kagaku</i> , <b>2004</b> , 53, 705-713	0.2	
20	Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , <b>2003</b> , 73, 554-65	6.1	393
19	Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 72, 209-19	6.1	264
18	Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. <i>Transplantation</i> , <b>2002</b> , 74, 571-2	1.8	141
17	Contribution of Angiotensin Converting Enzyme Gene Polymorphism to the Action of Angiotensin II Receptor Antagonist (CS-866).. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 33, 37-46	0	
16	Genetic polymorphisms and functional characterization of the 5Pflanking region of the human CYP2C9 gene: in vitro and in vivo studies. <i>Clinical Pharmacology and Therapeutics</i> , <b>2001</b> , 70, 175-82	6.1	61
15	Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. <i>Pharmacogenetics and Genomics</i> , <b>2001</b> , 11, 175-84		223
14	Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. <i>Pharmacogenetics and Genomics</i> , <b>2000</b> , 10, 85-9		125
13	Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 230-2	3.2	100
12	Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 237-44	3.2	73
11	Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. <i>British Journal of Clinical Pharmacology</i> , <b>1999</b> , 47, 115-9	3.8	37
10	The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. <i>Epilepsia</i> , <b>1998</b> , 39, 1317-23	6.4	144
9	Hydroxylation of Phenytoin (PHT) and the Cytochrome P450 (CYP) 2C Subfamily. <i>Epilepsia</i> , <b>1998</b> , 39, 82-83	6.4	4



8	Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. <i>Therapeutic Drug Monitoring</i> , <b>1998</b> , 20, 243-7	3.2	169
7	Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. <i>Clinical Pharmacology and Therapeutics</i> , <b>1996</b> , 59, 647-53	6.1	101
6	The effect of 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic side effects: in vivo and in vitro studies. <i>Psychiatry and Clinical Neurosciences</i> , <b>1995</b> , 49, S247-51	6.2	
5	Studies on pharmacoepidemiology of antiepileptic adverse reactions (2). <i>Psychiatry and Clinical Neurosciences</i> , <b>1991</b> , 45, 464-7	6.2	
4	The Effect of Phenytoin Withdrawal on Valproic Acid Free Fraction: A Case Report.. <i>Japanese Journal of Hospital Pharmacy</i> , <b>1991</b> , 17, 52-58		
3	Analysis of the factors influencing anti-epileptic drug concentrations--carbamazepine. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>1990</b> , 15, 337-49	2.2	1
2	Analysis of the factors influencing anti-epileptic drug concentrations--valproic acid. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>1990</b> , 15, 351-63	2.2	5
1	Predictive performance of Bayesian method in a simulation work: One-compartment open linear model containing an oral route.. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , <b>1988</b> , 19, 597-606	0	